Evidence mapPaperPMID 42445436Full record

ArticleTranslational cancer research2026

Complement system-related gene signatures implicated in the recurrence of glioma.

Yanqi Sun, Xiaozhang Bao, Yuheng Yang, Peinan Zhang, Nan Tian

Abstract read
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanqi Sun *College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Xiaozhang Bao *College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yuheng Yang *College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Peinan ZhangCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Nan TianCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0009-0009-4774-8888

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioma represents the most common primary malignant tumor of the central nervous system. The complement system, as a key component of the tumor microenvironment (TME), participates in tumor progression by mediating inflammatory responses and immune regulation. However, the specific mechanisms whereby complement system-related genes drive glioma recurrence remain unclear, and robust molecular biomarkers for recurrence prediction are absent. Therefore, this study aims to explore how these genes facilitate glioma progression and recurrence, and to construct a gene signature for recurrence risk prediction. Methods: By analyzing data from public databases Genotype-Tissue Expression (GTEx) and Chinese Glioma Genome Atlas (CGGA) and employing differential expression analysis, univariate Cox regression, multivariate Cox regression, and Bioinformatic regression analyses, we identified six core genes ( Results: Patients in the high-risk group exhibited significantly shorter overall survival (OS). At the mechanistic level, the expression of core genes was potentially closely associated with the Conclusions: This study provides a novel complement system-related gene-based predictive model for glioma recurrence, which may provide a potential biomarker for prognosis assessment and personalized treatment, as well as new insights into the role of the complement system in the immune microenvironment of glioma.

Indexed as

chemotherapy sensitivityComplement systemgliomaimmune landscapeprediction model

Identifiers

PMID42445436
PMCPMC13357098

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.